RxDoctor Payments Data

Temitope Adeyeye

Neurology · Douglasville, GANPI 1154785129

Payments from drug & device makers

$19,293in general payments, 2019–2025

Across 464 payments — averaging $41.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$13K
  • Pfizer$734
  • UCB, Inc.$587
  • Lundbeck LLC$416
  • Novartis$415
  • Neurocrine Biosciences, Inc.$391
  • plus $4K from 35 others

What the payments were for

  • Speaking & faculty fees$11,36959%
  • Travel & lodging$890%
  • Food & beverage$7,83541%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,293 in reported general payments places this provider in the 80th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$57,700
Medicare patients
177
Services billed
3,895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant106$157,269
IngrezzaValbenazine Tosylate15$113,469
Nurtec OdtRimegepant Sulfate56$100,283
QuliptaAtogepant64$80,156
Emgality PenGalcanezumab-Gnlm63$44,164
Aimovig AutoinjectorErenumab-Aooe30$21,371
Ajovy SyringeFremanezumab-Vfrm27$19,099
Ajovy AutoinjectorFremanezumab-Vfrm17$18,163
Gabapentin145$2,930
Sumatriptan Succinate40$2,304
Memantine Hcl92$1,458
Carbidopa-LevodopaCarbidopa/Levodopa46$1,057
Levetiracetam42$955
Galantamine ErGalantamine Hbr11$856
Primidone48$763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$12,963$237,425170 claims
Neurocrine Biosciences, Inc.Ingrezza$391$113,46915 claims
PfizerNurtec Odt$734$100,28356 claims
Upsher-smith Laboratories LLCTopiramate$298$44446 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 506 neurology providers in Georgia.

Other neurology in Douglasville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →